HBV Treatment: These studies examine the effectiveness of various antiviral and pegylated interferon drugs used either individually or in combination. These studies also examine the role of genotype, viral load, HBeAg status, and liver health in each treatment’s success or failure.

Adefovir

· 890. Durability of Adefovir Dipivoxil-Induced HBeAg Loss Following Long-term Additional Therapy in Patients with YMDD Mutants of Hepatitis B Virus

Clevudine

· 911. Clevudine Was Superior to Lamivudine in the Patients with HBeAg(+) Chronic Hepatitis B

Entecavir

· 969. Entecavir Induced HBV DNA Suppression at 12 Weeks in Treatment-Navie Patients with Chronic Hepatitis B is a Good Predictive Factor for Virological Response at 48 Weeks

Adefovir and Lamivudine Resistance

· 513. Addition of Adefovir Dipivoxil to Lamivudine in Chronic Hepatitis B Patients with YMDD Mutation: The long-term follow-up results

· 514. Demonstration of YMDD Mutation in Liver Tissues of 14 Chronic Hepatitis B Patients under Lamivudine Therapy

· 518. Hepatitis B Genotype Distribution and High Frequency of Lamivudine Resistance Mutations in Brazilian HIV/Hepatitis B Virus Co-infected Patients

· 888. Lamivudine-resistant Mutation Among Treatment-naive Hepatitis B Patients Is Common and May Be Associated with Treatment Failure

· 897. High Risk of Renal Impairment and Arterial Hypertension During Long-term Adefovir and Lamivudine Combination Therapy in Patients with Lamivudine-resistant Chronic Hepatitis B

Antiviral Resistance – General

· 884. Primary Resistance Mutations Against Nucleos(t)ide Analogues in Treatment-naïve Patients with HBV-infection

Children

· 1622. The Control of HBV Replication That Leads to HBeAg/anti-HBe Seroconversion Does Not Prevent the Emergence of Pre-Core Defective Variants in Genotype D-Infected Children

General

· 870. Higher Levels of HBV-DNA in Genotypes B and C Compared to Genotypes A and D

· 952. HBeAg Seroconversion Induced by Nucleos(t)ide Analogues in Chronic Hepatitis B Is Not Durable in a Majority of Cases

· 976. Cost-effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg-negative (-) Patients with Chronic Hepatitis B (CHB) in the USA

Tenofovir

· 842. Precore and Basal Core Promoter Mutations Restore the Reduced Replication Efficacy of Tenofovir-resistance Associated rtA194T Polymerase Mutations of the Hepatitis B Virus

· 866. Immunological Profile of Peripheral Blood Mononuclear Cells, NK T Cells and Dendritic Cells in Chronic HBV-infected Patients Treated with Tenofovir Disoproxil Fumarate

· 880. Presence of rtA194T at Baseline Does Not Reduce Efficacy to Tenofovir(TDF) in Patients with Lamivudine(LAM)-resistant Chronic Hepatitis B

· 907. Tenofovir-based Highly Active Antiretroviral Therapy (HAART) Is Associated with High Rates of HBV DNA Suppression and HBeAg Seroconversion in Thai HIV-HBV Coinfected Patients

· 913. Detection of Mutations Associated with Resistance to Nucleos(t)ide Analogs in Patients with HBV Infection During Treatment with Tenofovir

· 920. Higher Frequency of Selection of Tenofovir-resistant Mutations in Lamivudine Exposed Compared to Naïve CHBV Patients During Tenofovir Antiviral Therapy

· 932. Excellent Treatment Response to Tenofovir (TDF)Monotherapy in Chronic Hepatitis B (CHB) Patients with Prior Suboptimal Response to Entecavir (ETV) Monotherapy

· 955. Tenofovir is Equally Active In Vitro Against Wild-type HBV Clinical Isolates of Genotypes A−H

· 977. Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 MG QD

· 980. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B Participating in Studies 102 and 103

· 983. A Prospective Study of Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B Who Have Previously Failed Lamivudine and Have Significant Viral Replication Despite at Least 24 Weeks of Adefovir Dipivoxil Therapy

· 985. Combination of Entecavir and Tenofovir as a Rescue Therapy Is Safe and Highly Efficient in Cirrhotic HBV Mono-infected Patients with the History of Multiple Previous Treatment Failures